Regenxbio (RGNX) Gross Profit (2014 - 2024)

Regenxbio's Gross Profit history runs 11 years deep, the most recent figure standing at $14.9 million for Q4 2024.

• In Q4 2024, Gross Profit rose 35.73% year-over-year to $14.9 million; the TTM figure through Dec 2024 stood at $49.8 million (down 6.16% YoY), while the FY2024 annual figure was $49.8 million, down 6.16% from the prior year.
• Gross Profit was $14.9 million for Q4 2024 at Regenxbio, up from $11.8 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $375.6 million in Q4 2021 to a low of $6.5 million in Q1 2022.
• Historically, Gross Profit has averaged $34.9 million across 5 years, with a median of $13.7 million in 2021.
• The sharpest annual moves came in 2021 and 2022: Gross Profit surged 3257.14% in 2021, then plunged 95.06% in 2022.
• A 5-year view of Gross Profit shows it stood at $11.2 million in 2020, then soared by 3257.14% to $375.6 million in 2021, then slumped by 95.06% to $18.6 million in 2022, then slumped by 40.87% to $11.0 million in 2023, then jumped by 35.73% to $14.9 million in 2024.
• The last three Gross Profit figures came in at $14.9 million (Q4 2024), $11.8 million (Q3 2024), and $11.7 million (Q2 2024), per Business Quant data.